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Ouality of Life and Symptom Control
fter Stent Placement or Surgical Palliation
f Malignant Colorectal Obstruction
atish Nagula, MD, Nicole Ishill, MS, Carla Nash, MD, Arnold J Markowitz, MD, Mark A Schattner, MD,
arissa Temple, MD, FACS, Martin R Weiser, MD, FACS, Howard T Thaler, PhD, Ann Zauber, PhD,
ans Gerdes, MD
BACKGROUND: Emergent surgical management of malignant large bowel obstruction (LBO) carries a high rate
of morbidity and mortality. Self-expanding metal stents have emerged as an alternative for
palliation of malignant LBO. However, there are few long-term studies documenting the effect
of surgical palliation or colonic stents on symptoms or quality of life (QoL).
STUDY DESIGN: Between 2003 and 2006, patients with unresectable-for-cure malignancies presenting with
LBO were enrolled in this prospective study. Patients elected to undergo stent placement or
surgical palliation. Patients completed a symptom questionnaire and a QoL instrument (Func-
tional Assessment of CancerTherapy-Colorectal [FACT-C]) at weeks 1, 2, 4, 8, 12, and 24 after
palliation. Symptoms were assessed using the Colon Obstruction Score, a novel instrument
comprising nausea, vomiting, pain, distension, and bowel movement frequency scores.
RESULTS: Thirty patients had successful stent placement; 14 underwent surgical diversion. Colon Ob-
struction Scores immediately improved after both stent placement and surgery (p 0.05 for all
time points). Composite FACT-C scores progressively improved after stent placement (p 
NS), with the colon symptoms subscale improving after 1 month (p  0.05). FACT-C scores
declined initially after surgery and then returned to baseline, withmodest improvements seen in
the Colon Symptoms subscale (p  NS).
CONCLUSIONS: Both stent placement and surgical diversion provide durable improvement in symptoms from
LBO, as readily assessed by the Colon Obstruction Score. QoL is difficult to assess in terminal
cancer patients, but colon stent placement is associated with improved overall QoL and QoL
related to gastrointestinal symptoms. (J Am Coll Surg 2010;210:45–53. © 2010 by the
American College of Surgeons)
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Open access under CC BY-NC-ND license.alignant large bowel obstruction (LBO) is a common
ccurrence in patients with advanced cancer, usually from
olorectal and gynecologic malignancies. For patients with
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pen access under CC BY-NC-ND license.olorectal cancer, LBO typically occurs in the left colon.1,2
ymptoms generally include nausea, vomiting, abdominal
ain, distension, and altered bowel function.
Complete colonic obstruction is a surgical emergency,
hich can result in perforation, sepsis, and death. Surgical
anagement varies with site of obstruction, extent of dis-
ase, and local expertise. Surgical palliative procedures in-
lude the creation of a diverting colostomy/ileostomy or an
nternal bypass. Emergent surgical management has high
orbidity (50%) and a 30-day mortality approaching
0%.3,4 Stoma-related complications, including pain, skin
rritation, retraction, herniation, and stricture, occur in
0% to 40% of patients.5,6 Ostomies can cause psychoso-
ial stress, social restriction, and impact on daily function-
ng and quality of life (QoL).7-9
During the past 15 years, self-expanding metal stents
ave emerged as an alternative to surgery for palliation of
alignant LBO. Colon stents are readily inserted with an
ISSN 1072-7515
doi:10.1016/j.jamcollsurg.2009.09.039
e
o
(
q
a
o
Q
l
p
L
M
S
A
R
t
p
l
L
o
m
t
p
d
a
s
w
c
i
v
t
t
w
t
l
p
i
i
l
r
d
s
r
i
p
b
f
r
w
f
P
T
b
e
s
p
(
w
g
s
t
s
u
s
p
p
w
f
o
o
t
w
i
S
B
l
a
c
s
s
(
1
s
(
a
s
t
46 Nagula et al Malignant Colorectal Obstruction and Quality of Life J Am Coll Surgndoscopic procedure and provide immediate resolution of
bstructive symptoms with a high technical success rate
 95%) and complication rates of  10%.10,11 Conse-
uently, colon stent placement offers patients an enticing
lternative to surgery, obviating the need for an ostomy.
There are few longitudinal studies examining the effect
f stent placement or surgical diversion on symptoms or
oL. The aim of the present study is to assess QoL and
ongitudinal symptom control in patients after colon stent
lacement or surgical diversion for palliation of malignant
BO.
ETHODS
tudy design
pproval for this study was provided by the Institutional
eview Board of Memorial Sloan-Kettering Cancer Cen-
er.The study is a prospective observational cohort study of
atients with advanced malignancies undergoing either co-
on stent insertion or surgical diversion for malignant
BO. Patients were eligible for enrollment if they were
lder than the age of 18 years with an unresectable-for-cure
alignancy with clinical signs or symptoms of LBO be-
ween February 2002 and July 2006. Symptoms included
rogressive constipation, multiple small bowel movements
aily, abdominal distension, abdominal pain, and nausea
nd vomiting. LBO was confirmed in all patients by CT
can, gastrograffin enema, or colonoscopy. All patients
ere provided with detailed information about both surgi-
al diversion and colon stent placement.
Patients were excluded if they were unwilling to provide
nformed consent, had evidence of a perforation, had pre-
ious palliation for malignant bowel obstruction, had mul-
ifocal obstruction, or obstruction located within 2 cm of
he dentate line or proximal to the hepatic flexure. Patients
ere also excluded if they had a recent myocardial infarc-
ion or cerebrovascular accident or uncorrectable coagu-
opathy. After enrollment, patients were excluded if any
alliative procedures for LBOwere performed at an outside
nstitution. The study was initially designed as a random-
zed trial between colonic stent insertion and surgical pal-
iation, with an observational arm for patients declining
andomization. Because of patient reluctance to being ran-
Abbreviations and Acronyms
FACT-C  Functional Assessment of Cancer Therapy-
Colorectal
LBO  large bowel obstruction
QoL  quality of lifeomized, and the referring physician’s preference for either nurgery or stent placement, no patients were enrolled in the
andomized trial. Some patients feared the prospect of cop-
ng with an ostomy and opted for stent placement; other
atients elected for surgical diversion hoping for the possi-
ility of a concurrent resection. As the study progressed,
ewer patients were willing to consider surgical diversion, as
eferring physicians and patients became more familiar
ith colonic stents. All enrolled patients were prospectively
ollowed for 24 weeks after their intervention.
alliation
he technique for endoscopic colon stent insertion has
een described previously.12 Patients received tap-water en-
mas on the day of the procedure. Intravenous conscious
edation or general anesthesia was administered during the
rocedure. An Olympus flexible endoscope/colonoscope
GIF-1T40, PCF-140, or CF-140L; Olympus America)
as advanced to the site of obstruction. Using fluoroscopic
uidance, a guidewire was advanced across the obstructive
tricture. The stent deployment device was advanced over
he guidewire, and the stent was deployed under endo-
copic or fluoroscopic visualization, or both. The stents
sed were the Colonic Wallstent or the Colonic Ultraflex
tent (Boston Scientific) according to the endoscopist’s
reference.
Stent failure was defined as the technical inability to
lace a stent or no improvement of obstructive symptoms
ithin 48 hours. Patients with stent failure were referred
or surgical palliation.
Surgical palliative options included minimally invasive
r standard open diverting colostomy, diverting ileostomy,
r internal bypass. The type of operation and operative
echnique was chosen by the treating surgeon in discussion
ith the patient. Standard postoperative management was
ndividualized according to the primary surgical team.
ymptom and QoL assessment
aseline clinical and demographic information were col-
ected at the time of study enrollment. Symptoms were
ssessed using the Colon Obstruction Score, a novel, lo-
ally designed questionnaire that semiquantitatively as-
esses the presence and severity of abdominal pain, disten-
ion, nausea, vomiting, and bowel movement frequency
Table 1).Total scores ranged from 0 to 15 points; a score of
to 5 represents mild, 6 to 10 is moderate, and 11 to 15 is
evere obstructive symptoms.
The Functional Assessment of Cancer Therapy-Colorectal
FACT-C) tool is a validated survey instrument designed to
ssess QoL in cancer patients through physical, functional,
ocial, and emotional well-being subscales, with an addi-
ional subscale that evaluates QoL related to gastrointesti-
al function.13-15 The FACT-C was initially designed to
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47Vol. 210, No. 1, January 2010 Nagula et al Malignant Colorectal Obstruction and Quality of Lifessess QoL changes in colorectal cancer patients, but it is
ppropriate for study in patients with any malignancy that
ffects lower gastrointestinal tract function. Three individ-
al questions were administered along with the FACT-C,
valuating global QoL, global health, and the effort re-
uired to cope with illness.16,17
All patients underwent assessment of their symptoms
nd QoL using the previously mentioned instruments at
aseline before any palliative intervention. The same ques-
ionnaires were administered either in person or via tele-
hone at 1, 2, 4, 8, 12, and 24 weeks after stent insertion or
urgery. Surgical or endoscopic reinterventions and
rocedure-related complications were assessed at each
ollow-up interval.
tatistical analysis
verall survival was estimated using the product limit
ethod of Kaplan and Meier and was measured from 1
eek after study enrollment until death.This study was not
esigned as an intent-to-treat comparison between the
tent and surgical groups, but rather was designed to assess
ymptoms and QoL in patients who received colon stents
r who required surgical palliation, either initially or after
tent failure. A landmark analysis was used to examine dif-
erences in survival between final treatment groups, start-
ng at 1 week post-enrollment to account for patients who
nitially opted for stent placement but ultimately required
urgical palliation. Paired t-tests were used to determine
hether changes in subscale or symptom scores were sub-
tantially improved from baseline to follow-up time points,
ncluding only patients who were able to complete ques-
ionnaires at those time points. Medians and interquartile
anges were plotted over time for each of the subscales,
lobal questions, and symptom indices.
Although missing data occurred in some study patients
ecause of death or increased illness severity, no imputation
ethods were used, given that the primary goal was to
escribe the changes in QoL as a result of palliative treat-
ent, especially among those who would survive long
nough to benefit from it.
All analyses were performed using SAS 9.1 forWindows
able 1. Scoring for the Colon Obstruction Score
ategory 0 points 1
bdominal pain (0 [mild] to 10 [severe]) 0
bdominal distension None
owel movement frequency 23/d 1/d or
ausea None
omiting None
otal scores range from 0 to 15 points; a score of 1 to 5 represents mild; 6 toSAS Institute). cESULTS
ifty-one patients were initially enrolled in this prospective
ohort study. Seven patients were excluded from the final
nalysis: 1 patient withdrew consent; 2 were lost to
ollow-up before the first follow-up survey; 1 had a proto-
ol violation, because a surgical procedure was performed
t an outside institution; 1 did not have endoscopic evi-
ence of colonic obstruction; and 2 died before first
ollow-up from nonprocedural complications. Forty-four
atients were included in the final analysis (13 men, 31
omen, mean age 57 years); clinical and demographic
haracteristics are shown in Table 2. Enrolled patients had
broad range of cancers, with primary colorectal cancer in
1 patients (48%), ovarian cancer in 9 patients (20%),
astric cancer in 4 patients (9%), and a variety of other
alignancies in 10 patients (23%).
Stent placement was initially attempted in 38 patients
nd was successful in 32 (84%), including 100% success in
olorectal cancer (16 of 16) and 73% (16 of 22) in extra-
olonic malignancies. Eight patients experienced stent fail-
re and required surgical palliation, including 6 (16%)
ho had unsuccessful attempts at stent placement and 2
5%) who had successful stent placements but inadequate
ymptom resolution within 48 hours. Six patients chose
urgery initially, yielding a total of 14 in the surgery group
nd 30 in the stent group (Fig. 1). Two patients in the
urgical group underwent internal bypass, and the remain-
ng 12 had a diverting colostomy or ileostomy. Eight pa-
ients (26%) underwent stent placement as outpatients.
or those treated as inpatients, median length of stay was 4
ays after stent placement (22 patients) and 7.5 days after
urgery (14 patients). There were no procedure-related
omplications or postoperative deaths in either the stent
roup or the surgery group. There was 1 postoperative ab-
cess in the surgery group that required drainage.
Three patients (10%) in the stent group required repeat
olonoscopy with second stent placement: 2 for recurrent
bstruction caused by tumor ingrowth of the stent and 1
or stent migration. Small bowel obstruction developed in
additional patients in this group; 2 underwent surgical
ypass and 1 received a drainage gastrostomy. In the surgi-
t 2 points 3 points
4–6 7–10
Moderate Severe
for 2 d 48/d or none for 3 d  8/d or none for  4 d
Moderate Severe
Moderate Severe
moderate, and 11 to 15 is severe obstructive symptoms.poin
1–3
Mild
none
Mild
Mildal group, inoperable small bowel obstruction also devel-
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48 Nagula et al Malignant Colorectal Obstruction and Quality of Life J Am Coll Surgped in 3 patients (21%), who were managed with drain-
ge gastrostomy tubes.
Compliance with follow-up assessments was very good:
4% (41 of 44) of surviving patients completed surveys at
eek 1; 81% (34 of 42) at week 2; 74% (28 of 38) at week
; 76% (25 of 33) at week 8; 74% (20 of 27) at week 12;
nd 80% (16 of 20) at week 24. Median survival was 6
onths and did not differ between the 2 groups (Fig. 2).
able 2. Patient Characteristics
haracteristic
Stent (n 
n
ender
Male 8
Female 22
ancer type
Colon 16
Ovary 5
Stomach 3
Other 6
Breast 2
Unknown 1
Bladder 0
Cervical 1
Pancreatic 1
Gallbladder 0
Fallopian tube 0
Prostate 1
linical stage at LBO
III 1
IV 26
Recurrent 3
revious treatment
Surgery 2
Chemotherapy 7
Surgery  chemotherapy 11
Chemotherapy  radiation 1
Surgery  chemotherapy  radiation 4
None 5
ite of obstruction
Rectum 2
Rectosigmoid 10
Sigmoid 12
Descending colon 2
Splenic flexure 1
Transverse colon 2
Hepatic flexure 1
Stent median age, 59 y.
Surgery median age, 54 y.
Total (for group) median age, 57 y.
BO, large bowel obstruction.omponents of the Colon Obstruction Score were exam- gned individually; baseline scores are shown in Table 3. All
bstructive symptoms improved after the palliative proce-
ure, with most notable improvements in abdominal pain,
bdominal distension, and bowel movement frequency
cores. Plots of ColonObstruction Scores over time (Fig. 3)
llustrate a marked improvement in obstructive symptoms
n both the stent and surgical groups compared with base-
ine at week 1, week 4, and week 24 (p  0.05 for both
Surgery (n  14)† Total (n  44)‡
n % n %
5 36 13 30
9 64 31 70
5 36 21 48
4 29 9 20
1 7 4 9
4 29 10 23
0 2 5
0 1 2
1 7 1 2
0 1 2
1 7 2 5
1 7 1 2
1 7 1 2
0 1 2
0 1 2
12 86 38 86
2 14 5 11
0 2 5
2 14 9 2
7 50 18 41
0 1 2
1 7 5 11
4 29 9 20
2 14 4 9
5 36 15 34
4 29 16 36
0 2 2
1 7 2 2
0 2 2
2 14 3 730)*
%
27
73
53
17
10
20
7
3
3
3
3
3
87
10
7
23
37
3
13
17
7
33
40
7
3
7
3roups at all time points; Table 4). Obstruction scores pro-
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49Vol. 210, No. 1, January 2010 Nagula et al Malignant Colorectal Obstruction and Quality of Liferessively improved in the stent group throughout the
tudy period. Stent placement appeared equally efficacious
n patients with either colonic or extracolonic malignan-
ies, although patients with extracolonic cancers had
igher baseline scores (Fig. 4).
Composite FACT-C scores improved from baseline
ithin 2 weeks of stent placement and continued to pro-
ressively improve throughout the study period but did not
each statistical significance (Fig. 5). In the surgery group,
omposite FACT-C scores initially declined 2 weeks after
urgical palliation and then returned to baseline for the
emainder of the study. Small improvements were seen in
able 3. Baseline Colon Obstruction Score Components
nd Total Score
ategory
Stent
(n  30)
Surgery
(n  14)
All
(n  44)
bdominal pain 2 (23) 2 (12) 2 (13)
istension 2 (12) 1 (02) 2 (03)
owel movement score 2 (23) 2 (13) 2 (13)
ausea 1 (01) 1 (01) 1 (01)
omiting 0 (01) 0 (01) 0 (01)
olon Obstruction Score 6.5 (510) 6 (49) 6 (59)
ata are shown as median (interquartile range).The maximum score for each
Figure 1. Patient flow diagram.bomponent is 3, and the maximum total score is 15.he Physical, Functional, and Emotional subscales of the
ACT-C in both groups compared with baseline, with little
r no change seen in the Social Well-Being score in either
roup (Table 4). Progressive improvement in the Colon
ymptoms subscale of the FACT-C (Fig. 6) was seen in the
tent group throughout the study period (p 0.05 after 2
eeks compared with baseline) and in the surgery group
p  0.05 for all time points up to 12 weeks). Self-rated
verall QoL initially improved in both groups but declined
fter 8 weeks in the surgical group (p 0.05 for the surgery
roup at 4 and 8 weeks only; Fig. 7). Patients in both
roups also reported a mild improvement in the ability to
ope with their illness after their respective palliative pro-
edures (p 0.03 for stent group after 2 weeks) and a mild
mprovement in their overall general health (p  NS for
oth groups).
igure 2. Kaplan-Meier survival plots, starting 1 week after study
nrollment. Median survival was 6 months for each group.
igure 3. Colon Obstruction Scores for stent and surgery groups
lower scores represent improved obstructive symptoms). Vertical
ars represent interquartile range (IQR).
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50 Nagula et al Malignant Colorectal Obstruction and Quality of Life J Am Coll SurgISCUSSION
he ideal palliative procedure should provide effective re-
ief of symptoms, with a high technical success rate, a low
ate of complications, and a substantial improvement in
atients’ QoL. Multiple studies have documented a high
echnical success rate for stent placement in colonic malig-
igure 4. Colon Obstruction Scores, stent patients only, colorectal
ancer compared with extracolonic malignancies (lower scores rep-
esent improved obstructive symptoms). Vertical bars represent
able 4. Colon Obstruction Scores, FACT-C Scores, and FACT
nd 6 Months
ariable Baseline
olon Obstruction Score 6.5 (5.010.0)
ACT-C, overall 74.6 (60.783.2)
FACT subscales
Physical 11.7 (5.816.3)
Emotional 12.0 (10.015.0)
Functional 11.5 (10.016.0)
Social 25.0 (21.025.0)
Colon-Symptoms 10.0 (8.013.0)
ariable Baseline
olon Obstruction Score 6.0 (4.09.0)
ACT-C, overall 72.3 (65.580.0)
FACT subscales
Physical 11.7 (9.314.0)
Emotional 12.0 (9.018.0)
Functional 13.0 (11.016.0)
Social 23.0 (22.025.0)
Colon-Symptoms 11.0 (9.014.0)
ata are shown as median (interquartile range).
p  0.05 compared with baseline.
ACT-C, Functional Assessment of Cancer Therapy-Colorectal.nterquartile range (IQR). iancies, with few complications. Earlier studies were pri-
arily focused on technical success, and recent studies have
efined clinical success as “relief of obstructive symptoms”
ithout additional elaboration.18-20 Obstructive symptoms
an vary between individuals but typically include abdom-
nal pain, distention, nausea, vomiting, or altered bowel
ovement pattern. Our novel index, the Colon Obstruc-
igure 5. Composite Functional Assessment of Cancer Therapy-
olorectal (FACT-C) scores (higher scores represent improved qual-
ubscales for Surgery and Stent Group at Baseline, 1 Month,
Surgery (n  14)
1 Month 6 Months
2.5 (1.06.0)* 4.0 (05.0)*
79.5 (66.586.2) 77.5 (68.7105.2)
13.4 (10.517.5) 17.5 (10.522.2)
12.5 (9.017.0) 16.0 (14.016.0)
14.0 (12.016.0) 15.0 (11.023.0)
25.0 (23.025.0) 25.0 (23.025.0)
13.0 (11.021.0)* 16.0 (14.019.0)
Stent (n  30)
1 Month 6 Months
3.5 (2.05.0)* 2.0 (1.03.0)*
89.7 (72.099.3) 95.5 (74.099.8)
15.2 (10.522.2) 18.7 (14.021.0)
18.0 (12.020.0) 16.0 (12.022.0)
15.0 (12.018.0) 16.0 (12.018.0)
24.5 (23.024.5) 23.0 (19.024.0)
14.5 (12.020.0)* 21.0 (15.022.0)*-C Sty of life). Vertical bars represent interquartile range (IQR).
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51Vol. 210, No. 1, January 2010 Nagula et al Malignant Colorectal Obstruction and Quality of Lifeion Score, semiquantitatively captures this complex
onstellation of symptoms, which allows for assessment
f curative and palliative interventions on symptoms and
omparisons between patients and between published tri-
ls. The Colon Obstruction Score improved immediately
fter stent placement and progressively improved through-
ut the study period, reflecting the efficacy of colonic stents
n the palliation of symptoms from LBO. A similar early
mprovement in the Colon Obstruction Score was seen
fter surgery, but scores gradually worsened at later time
oints, possibly reflecting progressive abdominal disease.
Miner and colleagues have previously described the pro-
ound challenges in assessing QoL in advanced cancer pa-
ients.21 The benefit of a specific palliative procedure on
verall QoL is particularly difficult tomeasure, as declining
hysical status can dominate any QoL assessments. In ad-
ition, the high dropout rate because of patient mortality
an artificially inflate median QoL scores at later time
oints, as sicker patients die earlier in the study period.
iven these potential confounding issues, it is difficult to
onclude that colon stent placement or surgical diversion
ormalignant LBO yields a durable improvement in overall
oL in all patients. But for patients with a longer lifespan,
olon stent placement is associated with improved overall
oL.
One of the advantages of using the FACT-C is its reli-
nce on multiple subscales to derive an overall QoL score.
ecause terminal cancer patients have multiple health-
elated issues affecting theirQoL, it is logical to assume that
alliation of colonic obstruction would not necessarily
ave a dramatic effect on an individual’s physical, emo-
ional, functional, and social well-being.However, effective
igure 6. Colon Symptoms subscale of Functional Assessment of
ancer Therapy-Colorectal (higher scores represent improved quality
f life). Vertical bars represent interquartile range (IQR).alliation of LBO should not only confer improvement in sbstructive symptoms but should also yield an improve-
ent in the QoL associated with gastrointestinal symp-
oms, which are measured by the Colon Symptoms sub-
cale. Colon stent placement was associated with a gradual
nd continuous improvement in Colon Symptom subscale
cores throughout the entire study period, reaching statis-
ical significance after 4 weeks. Patients in the surgical
roup demonstrated an early improvement in Colon
ymptom subscale scores, which subsequently decreased
nd plateaued after 2 months.
Because these questionnaires can be difficult to admin-
ster in sick patients andmight not provide a precise answer
o the effect of palliative treatments, we also used 3 simple
uestions to assess self-rated global QoL, global health, and
he effort required to cope with illness. These questions
eemed to parallel the results seen with the FACT-C. Al-
hough they were easier to administer than the FACT-C,
hey offered only a small perspective of the effects that
alliative interventions have on patients.
The technical success rate for stent placement in patients
ith colorectal cancer in this study is similar to previously
ublished reports (between 90% and 100%). Colon stent
lacement in patients with extracolonic malignancies is a
ovel concept, with few reports in the literature.22-25 More
han half of the patients in this study (n  23) had extra-
olonic malignancies, with a lower technical success rate
or stent placement compared with colorectal cancer pa-
ients (72% vs 100%). The extrinsic compression and
olonic invasion by these malignancies distorts the usual
olonic and pelvic anatomy, resulting in sharp angulation; co-
onic fixation; and long, nontraversable strictures, markedly
imiting stent placement. In patients for whom stent place-
ent was successful, the improvement in the Colon Ob-
igure 7. Self-reported quality of life (QoL; higher scores represent
mproved QoL). Vertical bars represent interquartile range (IQR).truction Score and composite FACT-C score was similar,
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52 Nagula et al Malignant Colorectal Obstruction and Quality of Life J Am Coll Surgemonstrating colon stents are equally efficacious regard-
ess of cancer type. This is in contrast to a recent study that
uggests colon stents are ineffective in patients with LBO
rom extracolonic malignancies.25
This prospective study was initially designed as a ran-
omized controlled trial between endoscopic and surgical
alliation of malignant LBO. Patients and their physicians
eclined to have the selection of their treatment subjected
o randomization, thus introducing a self-selection bias.
he study was not powered to draw statistical conclusions
etween the stent and surgery groups or to detect small
hanges in the Colon Obstruction Score or FACT-C. De-
pite high compliance with survey completion, the sub-
tantial patient dropout rate because of the high mortality
elated to advanced malignancy limited our ability to draw
tatistical conclusions, especially at the later time points (at
, 12, and 24 weeks). Statistically significant p values
chieved at the later time points should be interpreted with
aution.
This is the first prospective study evaluating QoL and
ymptoms in patients undergoing palliation for malignant
BO. Both colon stent placement and surgical diversion
re equally efficacious at palliating the symptoms of LBO,
s readily assessed by the Colon Obstruction Score. Al-
hough neither stent placement nor surgery is associated
ith improvement in overall QoL, stent placement is asso-
iated with improved QoL related to gastrointestinal
unction.
The decision to proceed with either colon stent place-
ent or surgical diversion should be individualized to each
articular patient.Themode of palliation should be chosen
fter careful discussion with the patient and the oncologist
bout the potential limitations of each procedure. Sicker
atients who might not withstand an operation might be
etter suited for colon stent placement; but long-term de-
initive palliation of bowel obstruction in younger, health-
er patients can best be achieved with surgical diversion.
he need for immediate postprocedure chemotherapy fa-
ors stent placement. The natural progression of disease
hat occurs in patients with advanced abdominal malig-
ancies will inevitably result in development of additional
r recurrent symptoms, regardless of the method of pallia-
ion chosen.21
Although one-fifth of patients in the original stent
roup ultimately required surgical palliation, colon
tent placement remains a viable primary palliative op-
ion, given its high technical success rate, low complica-
ion rate, high efficacy in symptom palliation, improve-
ent in QoL, and reduction in hospital length of stay.
dditionally, we have introduced the Colon Obstruc-
ion Score as a novel symptom index that could be ad-itionally validated and used in future prospective stud-
es evaluating outcomes in the management of
alignant LBO.This report adds to the growing body of
iterature supporting use of colonic stents for palliation
f malignant colonic obstruction.
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